利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.022 秒)

    1,2,4-triazine-4-amine derivatives
    4.
    发明授权
    1,2,4-triazine-4-amine derivatives 有权
    1,2,4-三嗪-4-胺衍生物

    公开(公告)号：US08809525B2

    公开(公告)日：2014-08-19

    申请号：US13576798

    申请日：2011-02-07

    申请人： Miles Stuart Congreve ,  Stephen Philippe Andrews ,  Jonathan Stephen Mason ,  Christine Mary Richardson ,  Giles Albert Brown

    发明人： Miles Stuart Congreve ,  Stephen Philippe Andrews ,  Jonathan Stephen Mason ,  Christine Mary Richardson ,  Giles Albert Brown

    IPC分类号： C07D401/04 ,  C07D401/14 ,  A61K31/444 ,  A61P25/16 ,  C07D417/12 ,  C07D405/04 ,  C07D413/04 ,  C07D405/10 ,  C07D487/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D253/07

    CPC分类号： C07D401/04 ,  A61K31/4427 ,  A61K31/506 ,  A61K31/53 ,  A61K31/5355 ,  A61K31/5377 ,  A61K31/5386 ,  C07D253/07 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D405/04 ,  C07D405/10 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04

    摘要： According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1-A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy2 group is optionally substituted by one or more R4c substituents; HetB represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which HetB group is optionally substituted by one or more R4d substituents.

    摘要翻译： 根据本发明，提供式A1化合物，其可用于治疗通过抑制A1-A2b或特别是A2a受体而改善的病症或障碍，其中式A1化合物具有结构， 其中，A表示Cy1或HetA; Cy1表示5至14元芳族，完全饱和或部分不饱和的碳环系统，其包含一个，两个或三个环，该Cy1基团任选被一个或多个R 4a取代基取代; HetA表示5至14元杂环基，其可以是芳族的，完全饱和的或部分不饱和的，并且其含有一个或多个选自O，S和N的杂原子，该杂环基可以包含一个，两个或三个环， HetA基团任选被一个或多个R 4b取代基取代; B代表Cy2或HetB; Cy2表示包含一个或两个环的3-至10-元芳族，完全饱和或部分不饱和的碳环系，该Cy2基团任选被一个或多个R 4c取代基取代; HetB表示可以是芳族的，完全饱和的或部分不饱和的并且含有一个或多个选自O，S和N的杂原子的3-至10-元杂环基，该杂环基可以包含一个或两个环，并且HetB基团 任选地被一个或多个R 4d取代基取代。